{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:09:15Z","timestamp":1791230955840,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89862-9","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T09:01:59Z","timestamp":1747213319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world evidence couples genomic biomarkers with therapeutic outcomes for canine hemangiosarcoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Lucas","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"89862_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","volume":"11","author":"RJ Young","year":"2010","unstructured":"Young, R. J. et al. Lancet Oncol. 11, 983\u2013991 (2010).","journal-title":"Lancet Oncol."},{"key":"89862_CR2","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z","volume":"77","author":"RJ Mark","year":"1996","unstructured":"Mark, R. J., Poen, J. C., Tran, L. M., Fu, Y. S. & Juillard, G. F. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 77, 2400\u20132406 (1996).","journal-title":"Cancer"},{"key":"89862_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1200\/JCO.2017.74.9812","volume":"36","author":"JA Khan","year":"2018","unstructured":"Khan, J. A., Maki, R. G. & Ravi, V. Pathologic angiogenesis of malignant vascular sarcomas: Implications for treatment. J. Clin. Oncol. 36, 194\u2013201 (2018).","journal-title":"J. Clin. Oncol."},{"key":"89862_CR4","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1158\/1541-7786.MCR-19-0221","volume":"17","author":"K Megquier","year":"2019","unstructured":"Megquier, K. et al. Comparative genomics reveals shared mutational landscape in canine hemangiosarcoma and human angiosarcoma. Mol. Cancer Res. 17, 2410\u20132421 (2019).","journal-title":"Mol. Cancer Res."},{"key":"89862_CR5","doi-asserted-by":"publisher","first-page":"e0264986","DOI":"10.1371\/journal.pone.0264986","volume":"17","author":"S Wong","year":"2022","unstructured":"Wong, S. et al. Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients. PLoS ONE. 17, e0264986 (2022).","journal-title":"PLoS ONE"},{"key":"89862_CR6","doi-asserted-by":"publisher","first-page":"e0229728","DOI":"10.1371\/journal.pone.0229728","volume":"15","author":"G Wang","year":"2020","unstructured":"Wang, G. et al. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma. PLoS ONE. 15, e0229728 (2020).","journal-title":"PLoS ONE"},{"key":"89862_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2018.01.012","volume":"188","author":"DL Gustafson","year":"2018","unstructured":"Gustafson, D. L., Duval, D. L., Regan, D. P. & Thamm, D. H. Canine sarcomas as a surrogate for the human disease. Pharmacol. Ther. 188, 80\u201396 (2018).","journal-title":"Pharmacol. Ther."},{"key":"89862_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/17474124.2021.1945920","volume":"15","author":"BL Juin Hsien","year":"2021","unstructured":"Juin Hsien, B. L. & Shelat, V. G. Spleen angiosarcoma: A world review. Expert Rev. Gastroenterol. Hepatol. 15, 1115\u20131141 (2021).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"89862_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2022.04.030","volume":"171","author":"F Conforti","year":"2022","unstructured":"Conforti, F. et al. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective European study. Eur. J. Cancer. 171, 183\u2013192 (2022).","journal-title":"Eur. J. Cancer"},{"key":"89862_CR10","doi-asserted-by":"crossref","unstructured":"Gambardella, V. et al. Personalized Medicine: Recent Progress in Cancer Therapy. Cancers 12, (2020).","DOI":"10.3390\/cancers12041009"},{"key":"89862_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","volume":"14","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas, E., Tsimberidou, A. M., Vo, H. H. & Kurzrock, R. Clinical trial design in the era of precision medicine. Genome Med. 14, 101 (2022).","journal-title":"Genome Med."},{"key":"89862_CR12","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1093\/neuonc\/noab209","volume":"23","author":"TS Armstrong","year":"2021","unstructured":"Armstrong, T. S. & Gilbert, M. R. Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors. Neuro Oncol. 23, S30\u2013S38 (2021).","journal-title":"Neuro Oncol."},{"key":"89862_CR13","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-12-0893","volume":"12","author":"NJ Andersen","year":"2013","unstructured":"Andersen, N. J. et al. Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. Mol. Cancer Ther. 12, 1701\u20131714 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"89862_CR14","doi-asserted-by":"crossref","unstructured":"Dobson, J. M. Breed-predispositions to cancer in pedigree dogs. ISRN Vet. Sci. 941275 (2013).","DOI":"10.1155\/2013\/941275"},{"key":"89862_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12917-017-1126-0","volume":"13","author":"E Baioni","year":"2017","unstructured":"Baioni, E. et al. Estimating canine cancer incidence: Findings from a population-based tumour registry in northwestern Italy. BMC Vet. Res. 13, 203 (2017).","journal-title":"BMC Vet. Res."},{"key":"89862_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/vco.12839","volume":"20","author":"SM Schwartz","year":"2022","unstructured":"Schwartz, S. M. et al. Lifetime prevalence of malignant and benign tumours in companion dogs: Cross-sectional analysis of dog aging project baseline survey. Vet. Comp. Oncol. 20, 797\u2013804 (2022).","journal-title":"Vet. Comp. Oncol."},{"key":"89862_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/vco.12519","volume":"17","author":"L Marconato","year":"2019","unstructured":"Marconato, L. et al. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian society of Veterinary Oncology. Vet. Comp. Oncol. 17, 537\u2013544 (2019).","journal-title":"Vet. Comp. Oncol."},{"key":"89862_CR18","first-page":"967","volume":"59","author":"K Batschinski","year":"2018","unstructured":"Batschinski, K. et al. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005\u20132014). Can. Vet. J. 59, 967\u2013972 (2018).","journal-title":"Can. Vet. J."},{"key":"89862_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","volume":"4","author":"N Chalhoub","year":"2009","unstructured":"Chalhoub, N. & Baker, S. J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4, 127\u2013150 (2009).","journal-title":"Annu. Rev. Pathol."},{"key":"89862_CR20","doi-asserted-by":"publisher","first-page":"10935","DOI":"10.1038\/s41598-023-37505-2","volume":"13","author":"L Rodrigues","year":"2023","unstructured":"Rodrigues, L. et al. Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics. Sci. Rep. 13, 10935 (2023).","journal-title":"Sci. Rep."},{"key":"89862_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.tig.2023.02.009","volume":"39","author":"P Aguilera","year":"2023","unstructured":"Aguilera, P. & L\u00f3pez-Contreras, A. J. ATRX, a guardian of chromatin. Trends Genet. 39, 505\u2013519 (2023).","journal-title":"Trends Genet."},{"key":"89862_CR22","first-page":"209","volume":"18","author":"KU Sorenmo","year":"2004","unstructured":"Sorenmo, K. U. et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J. Vet. Intern. Med. 18, 209\u2013213 (2004).","journal-title":"J. Vet. Intern. Med."},{"key":"89862_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1939-1676.1996.tb02085.x","volume":"10","author":"GK Ogilvie","year":"1996","unstructured":"Ogilvie, G. K., Powers, B. E., Mallinckrodt, C. H. & Withrow, S. J. Surgery and doxorubicin in dogs with hemangiosarcoma. J. Vet. Intern. Med. 10, 379\u2013384 (1996).","journal-title":"J. Vet. Intern. Med."},{"key":"89862_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2460\/javma.247.4.393","volume":"247","author":"KM Wendelburg","year":"2015","unstructured":"Wendelburg, K. M. et al. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001\u20132012). J. Am. Vet. Med. Assoc. 247, 393\u2013403 (2015).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"89862_CR25","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00105-019-4462-0","volume":"70","author":"N B\u00f6nisch","year":"2019","unstructured":"B\u00f6nisch, N., Langan, E. A. & Terheyden, P. [Cutaneous angiosarcoma: Radiochemotherapy with liposomal pegylated doxorubicin]. Hautarzt 70, 700\u2013706 (2019).","journal-title":"Hautarzt"},{"key":"89862_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","volume":"26","author":"CA Painter","year":"2020","unstructured":"Painter, C. A. et al. The Angiosarcoma Project: Enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat. Med. 26, 181\u2013187 (2020).","journal-title":"Nat. Med."},{"key":"89862_CR27","doi-asserted-by":"crossref","unstructured":"Espejo-Freire, A. P. et al. Genomic landscape of angiosarcoma: A targeted and immunotherapy biomarker analysis. Cancers 13, (2021).","DOI":"10.3390\/cancers13194816"},{"key":"89862_CR28","doi-asserted-by":"publisher","first-page":"36041","DOI":"10.18632\/oncotarget.5936","volume":"6","author":"R Murali","year":"2015","unstructured":"Murali, R. et al. Targeted massively parallel sequencing of Angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget 6, 36041\u201336052 (2015).","journal-title":"Oncotarget"},{"key":"89862_CR29","doi-asserted-by":"publisher","first-page":"e1167158","DOI":"10.1080\/23723556.2016.1167158","volume":"3","author":"C Koschmann","year":"2016","unstructured":"Koschmann, C., Lowenstein, P. R. & Castro, M. G. ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Mol. Cell. Oncol. 3, e1167158 (2016).","journal-title":"Mol. Cell. Oncol."},{"key":"89862_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2165\/00003495-200767030-00004","volume":"67","author":"JJ Augustine","year":"2007","unstructured":"Augustine, J. J., Bodziak, K. A. & Hricik, D. E. Use of sirolimus in solid organ transplantation. Drugs 67, 369\u2013391 (2007).","journal-title":"Drugs"},{"key":"89862_CR31","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack, F. X. et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med. 364, 1595\u20131606 (2011).","journal-title":"N. Engl. J. Med."},{"key":"89862_CR32","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","volume":"18","author":"F Meric-Bernstam","year":"2012","unstructured":"Meric-Bernstam, F. et al. PIK3CA\/PTEN mutations and akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin. Cancer Res. 18, 1777\u20131789 (2012).","journal-title":"Clin. Cancer Res."},{"issue":"Suppl 2","key":"89862_CR33","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1038\/onc.2009.352","volume":"27","author":"S Menon","year":"2008","unstructured":"Menon, S. & Manning, B. D. Common corruption of the mTOR signaling network in human tumors. Oncogene 27 (Suppl 2), S43\u201351 (2008).","journal-title":"Oncogene"},{"key":"89862_CR34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/bcp.12958","volume":"82","author":"LS Steelman","year":"2016","unstructured":"Steelman, L. S. et al. The therapeutic potential of mTOR inhibitors in breast cancer. Br. J. Clin. Pharmacol. 82, 1189\u20131212 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"89862_CR35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/ijc.24837","volume":"126","author":"A Shafer","year":"2010","unstructured":"Shafer, A., Zhou, C., Gehrig, P. A., Boggess, J. F. & Bae-Jump, V. L. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int. J. Cancer. 126, 1144\u20131154 (2010).","journal-title":"Int. J. Cancer"},{"key":"89862_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.phrs.2016.03.007","volume":"107","author":"HL Vu","year":"2016","unstructured":"Vu, H. L. & Aplin, A. E. Targeting mutant NRAS signaling pathways in melanoma. Pharmacol. Res. 107, 111\u2013116 (2016).","journal-title":"Pharmacol. Res."},{"key":"89862_CR37","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"issue":"10.1\u201333","key":"89862_CR38","first-page":"11","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: The genome analysis toolkit best practices pipeline. Curr. Protoc. Bioinf. 43 (10.1\u201333), 11 (2013).","journal-title":"Curr. Protoc. Bioinf."},{"key":"89862_CR39","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/bioinformatics\/btr174","volume":"27","author":"DW Barnett","year":"2011","unstructured":"Barnett, D. W., Garrison, E. K., Quinlan, A. R., Str\u00f6mberg, M. P. & Marth, G. T. BamTools: A C\u2009+\u2009+\u2009API and toolkit for analyzing and managing BAM files. Bioinformatics 27, 1691\u20131692 (2011).","journal-title":"Bioinformatics"},{"key":"89862_CR40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.21105\/joss.01317","volume":"4","author":"C Davidson-Pilon","year":"2019","unstructured":"Davidson-Pilon, C. Lifelines: Survival analysis in Python. J. Open. Source Softw. 4, 1317 (2019).","journal-title":"J. Open. Source Softw."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89862-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89862-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89862-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T09:02:05Z","timestamp":1747213325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89862-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89862"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89862-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"2 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted by The One Health Company and its FidoCure\u00ae Partners, Stanford University, L.R., K.W., G.H., G.P., L.L., A.M., A.H., C.L. and J.Z. are part time, full time employees or consultants of the company. The authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: employment and compensation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16442"}}